Response to Pegylated Interferon Plus Ribavirin in Patients with Hepatitis C Virus Genotype 6a Infection from Guangdong and Guangxi Province of China
Joint Authors
Gao, Zhiliang
Zhu, Jianyun
Zhang, Xiao-hong
Tong, Wangxia
Luo, Ning
Yang, Xiaohua
Lei, Zhiying
Huang, Xiaoliang
Zhao, Zhixin
Jiang, Zhonghua
Source
Gastroenterology Research and Practice
Issue
Vol. 2016, Issue 2016 (31 Dec. 2015), pp.1-6, 6 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2016-02-28
Country of Publication
Egypt
No. of Pages
6
Main Subjects
Abstract EN
Aim.
Our aim is to survey the treatment effect of PEG-IFN plus ribavirin in patients infected with HCV genotype 6a in Guangdong and Guangxi province of China and investigate best course of antiviral treatment for patients with HCV-6a infection.
Methods.
515 eligible patients received subcutaneous 180 μg PEG-IFNα-2a or 1.5 μg/kg PEG-IFNα-2b once weekly plus oral ribavirin.
Primary outcome was SVR by intention-to-treat analysis.
Secondary outcome was RVR, cEVR, ETR, and relapse rate.
Results.
SVR in patients with HCV-6a infection treated for 48 weeks was comparable to that in patients with HCV-2/3 infection (80.9% versus 82.5%, p = 0.812 ) and higher than that in patients with HCV-1b infection (80.9% versus 67.2%, p = 0.014 ).
ETR (98.9% versus 90.6%, p = 0.016 ), virological response at month 3 of end-of- treatment (88.8% versus 76.6%, p = 0.044 ), SVR (80.9% versus 65.6%, p = 0.032 ), and virological response at month 12 of end-of-treatment (76.4% versus 60.9%, p = 0.04 ) in patients with HCV-6a infection treated for 48 weeks were higher than those in patients with HCV-6a infection treated for 24 weeks.
Conclusion.
SVR in patients with HCV-6a treated for 48 weeks was comparable to that in patients with HCV-2/3 infection and higher than that in patients with HCV-1b infection; patients with HCV-6a infection treated for 48 weeks had a superior treatment response than patients treated for 24 weeks.
American Psychological Association (APA)
Tong, Wangxia& Zhu, Jianyun& Luo, Ning& Yang, Xiaohua& Lei, Zhiying& Huang, Xiaoliang…[et al.]. 2016. Response to Pegylated Interferon Plus Ribavirin in Patients with Hepatitis C Virus Genotype 6a Infection from Guangdong and Guangxi Province of China. Gastroenterology Research and Practice،Vol. 2016, no. 2016, pp.1-6.
https://search.emarefa.net/detail/BIM-1104711
Modern Language Association (MLA)
Tong, Wangxia…[et al.]. Response to Pegylated Interferon Plus Ribavirin in Patients with Hepatitis C Virus Genotype 6a Infection from Guangdong and Guangxi Province of China. Gastroenterology Research and Practice Vol. 2016, no. 2016 (2015), pp.1-6.
https://search.emarefa.net/detail/BIM-1104711
American Medical Association (AMA)
Tong, Wangxia& Zhu, Jianyun& Luo, Ning& Yang, Xiaohua& Lei, Zhiying& Huang, Xiaoliang…[et al.]. Response to Pegylated Interferon Plus Ribavirin in Patients with Hepatitis C Virus Genotype 6a Infection from Guangdong and Guangxi Province of China. Gastroenterology Research and Practice. 2016. Vol. 2016, no. 2016, pp.1-6.
https://search.emarefa.net/detail/BIM-1104711
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1104711